Palvella Therapeutics (PVLA) Capital Expenditures Growth (3y) (2017 - 2023)
Powered by 
Analysis
Palvella Therapeutics (PVLA) Capital Expenditures Growth (3y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 23.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 63.07% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -45.93% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -40.95% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 29.63% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 60.74% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.08% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -26.46% |
| Sep 30, 2023 | 27.69% |
| Jun 30, 2023 | -60.18% |
| Mar 31, 2023 | -70.80% |
| Dec 31, 2022 | -26.19% |
| Sep 30, 2022 | -47.28% |
| Jun 30, 2022 | -12.32% |
| Mar 31, 2022 | 47.59% |
| Dec 31, 2021 | -15.41% |
| Sep 30, 2021 | 2.50% |
| Jun 30, 2021 | -16.55% |
| Mar 31, 2021 | -59.26% |
| Dec 31, 2020 | -10.97% |
| Sep 30, 2020 | -69.93% |
| Jun 30, 2020 | 16.97% |
| Mar 31, 2020 | 120.81% |
| Dec 31, 2019 | 70.49% |
| Sep 30, 2019 | 5.41% |
| Jun 30, 2019 | 154.37% |
| Mar 31, 2019 | 21.23% |